201 related articles for article (PubMed ID: 11984079)
1. Treatment of myeloma: recent developments.
Zweegman S; Huijgens PC
Anticancer Drugs; 2002 Apr; 13(4):339-51. PubMed ID: 11984079
[TBL] [Abstract][Full Text] [Related]
2. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
3. A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
Chang HJ; Lee JH; Do YR; Bae SH; Lee JL; Nam SH; Yoon SS; Bang SM
Korean J Intern Med; 2011 Dec; 26(4):403-9. PubMed ID: 22205840
[TBL] [Abstract][Full Text] [Related]
4. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
[TBL] [Abstract][Full Text] [Related]
5. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
6. Treatment of multiple myeloma: an emphasis on new developments.
Kyle RA; Vincent Rajkumar S
Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
[TBL] [Abstract][Full Text] [Related]
7. [Multiple myeloma and other plasma cell dyscrasias].
del Potro Gómez E; Morales Sanz D
Rev Clin Esp; 1999 Apr; 199 Suppl 1():52-7. PubMed ID: 10422451
[No Abstract] [Full Text] [Related]
8. Haematopoietic stem-cell transplantation in multiple myeloma.
Handelsman H
Cancer Treat Rev; 1996 Mar; 22(2):119-25. PubMed ID: 8665564
[No Abstract] [Full Text] [Related]
9. [New treatment of multiple myeloma].
Hulin C
Rev Med Interne; 2007 Oct; 28(10):682-8. PubMed ID: 17559982
[TBL] [Abstract][Full Text] [Related]
10. Is the low-thalidomide dose MPT regimen beneficial?
Min CK
Korean J Intern Med; 2011 Dec; 26(4):400-2. PubMed ID: 22205839
[No Abstract] [Full Text] [Related]
11. The importance of complete response in outcomes in myeloma.
Nooka A; Kaufman J; Lonial S
Cancer J; 2009; 15(6):465-72. PubMed ID: 20010165
[TBL] [Abstract][Full Text] [Related]
12. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.
Raaijmakers HG; Izquierdo MA; Lokhorst HM; de Leeuw C; Belien JA; Bloem AC; Dekker AW; Scheper RJ; Sonneveld P
Blood; 1998 Feb; 91(3):1029-36. PubMed ID: 9446666
[TBL] [Abstract][Full Text] [Related]
13. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
15. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
18. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
19. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
20. Triple MEL100 therapy in multiple myeloma.
Berz D; Colvin GA; McCormack EM; Winer ES; Karwan P; Colvin L; Rathore R; Lum LG; Elfenbein GJ; Quesenberry PJ
Transplant Proc; 2009 Nov; 41(9):3863-7. PubMed ID: 19917402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]